atorvastatin has been researched along with Multiple Myeloma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Panasenko, M; Samura, B | 1 |
| Altun, A; Şencan, M; Terzi, H | 1 |
| Hou, T; Lee, SM; Li, P; Li, S; Li, Y; Pan, P; Shen, M; Yu, H; Zhang, L; Zhou, S | 1 |
| Samura, B | 1 |
4 other study(ies) available for atorvastatin and Multiple Myeloma
| Article | Year |
|---|---|
SST2 AS A PREDICTOR OF STATIN TREATMENT EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA.
Topics: Atorvastatin; Biomarkers; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multiple Myeloma; Prognosis; Treatment Outcome | 2022 |
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multiple Myeloma; Simvastatin | 2019 |
Discovery of Rho-kinase inhibitors by docking-based virtual screening.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Cerebral Hemorrhage; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Female; HeLa Cells; Heptanoic Acids; Humans; Lung Neoplasms; Models, Molecular; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Multiple Myeloma; Protein Kinase Inhibitors; Pyrroles; rho-Associated Kinases; Zebrafish | 2013 |
GALECTIN-3 AS A PREDICTOR OF STATIN TREATMENT EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Dyslipidemias; Female; Galectin 3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multiple Myeloma; Treatment Outcome | 2016 |